Danbury based Mannkind expects to triple the manufacturing of Afrezza, an inhalable form of insulin approved last summer by the FDA. DANBURY -- Executives with Mannkind are tripling their production capacity at their local manufacturing facility in the hopes that demand for their drug Afrezza will continue to increase in the coming months.
via Danbury Newswire http://ift.tt/1Ox0N7q
Ridgefield High School Announces 2023-2024 Q3 Honor Roll Students - Patch
-
Ridgefield High School Announces 2023-2024 Q3 Honor Roll Students Patch
9 hours ago
No comments:
Post a Comment